DK2206719T3 - A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN - Google Patents

A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN Download PDF

Info

Publication number
DK2206719T3
DK2206719T3 DK10150763.0T DK10150763T DK2206719T3 DK 2206719 T3 DK2206719 T3 DK 2206719T3 DK 10150763 T DK10150763 T DK 10150763T DK 2206719 T3 DK2206719 T3 DK 2206719T3
Authority
DK
Denmark
Prior art keywords
compound
compounds
androsta
diene
mice
Prior art date
Application number
DK10150763.0T
Other languages
Danish (da)
English (en)
Inventor
Angela Brodie
Vincent Njar
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of DK2206719T3 publication Critical patent/DK2206719T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK10150763.0T 2005-03-02 2006-03-02 A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN DK2206719T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65739005P 2005-03-02 2005-03-02
EP06736460A EP1853619B1 (en) 2005-03-02 2006-03-02 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene for use in the treatment of a prostate disease

Publications (1)

Publication Number Publication Date
DK2206719T3 true DK2206719T3 (en) 2015-01-26

Family

ID=36941503

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10150763.0T DK2206719T3 (en) 2005-03-02 2006-03-02 A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN
DK06736460.4T DK1853619T3 (da) 2005-03-02 2006-03-02 3-beta-hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-dien til anvendelse ved behandling af prostatasygdomme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06736460.4T DK1853619T3 (da) 2005-03-02 2006-03-02 3-beta-hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-dien til anvendelse ved behandling af prostatasygdomme

Country Status (21)

Country Link
US (1) US7875599B2 (enExample)
EP (2) EP1853619B1 (enExample)
JP (2) JP5130453B2 (enExample)
KR (1) KR101380959B1 (enExample)
CN (2) CN101155823A (enExample)
AT (1) ATE482969T1 (enExample)
AU (1) AU2006218711B2 (enExample)
BR (1) BRPI0607523A2 (enExample)
CA (1) CA2599953C (enExample)
DE (1) DE602006017175D1 (enExample)
DK (2) DK2206719T3 (enExample)
EA (1) EA019560B1 (enExample)
ES (2) ES2528055T3 (enExample)
IL (3) IL185608A (enExample)
MX (1) MX2007010593A (enExample)
NZ (1) NZ561571A (enExample)
PL (2) PL1853619T3 (enExample)
PT (2) PT2206719E (enExample)
SI (2) SI1853619T1 (enExample)
WO (1) WO2006093993A1 (enExample)
ZA (1) ZA200708106B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
EA019560B1 (ru) * 2005-03-02 2014-04-30 Юнивесити Оф Мэриленд, Балтимор Способ лечения простаты (варианты)
US20100047338A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2008154402A2 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
GB2470873A (en) * 2008-03-12 2010-12-08 Univ Maryland Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20110118219A1 (en) * 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
WO2010024930A2 (en) 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
US20100105700A1 (en) * 2008-10-28 2010-04-29 Lead Therapeutics, Inc. Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
GB2514957A (en) * 2009-02-05 2014-12-10 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
US8791095B2 (en) 2009-02-05 2014-07-29 Tokai Pharmaceuticals, Inc. Steroidal CYP17 inhibitors/antiandrogens
AU2010210422A1 (en) * 2009-02-05 2011-08-18 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
UY32730A (es) 2009-06-26 2011-01-31 Novartis Ag Inhibidores de cyp17
AU2010279398A1 (en) * 2009-08-07 2012-03-08 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
EP2499151A4 (en) * 2009-11-13 2013-03-20 Tokai Pharmaceuticals Inc MAMMALIAN STEROID METABOLITES
CA2782266A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
WO2012083112A2 (en) * 2010-12-16 2012-06-21 Biomarin Pharmaceutical Inc. Cyp11b, cyp17, and/or cyp21 inhibitors
MX359399B (es) 2011-04-28 2018-09-27 Novartis Ag Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
JP2014523445A (ja) * 2011-07-18 2014-09-11 トーカイ ファーマシューティカルズ，インク． 前立腺癌を処置するための新規な組成物及び方法
US20150005265A1 (en) * 2011-12-22 2015-01-01 Susan Stewart Methods and compositions for combination therapy using p13k/mtor inhibitores
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
EP2991644B1 (en) 2013-04-04 2020-03-25 University of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
ES2709480T3 (es) 2013-12-24 2019-04-16 Harvard College Análogos de cortistatina y síntesis y usos de los mismos
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
CN105732759A (zh) * 2015-01-29 2016-07-06 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2017004411A1 (en) 2015-07-01 2017-01-05 President And Fellows Of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017066697A1 (en) 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
IT201600083406A1 (it) * 2016-08-08 2018-02-08 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
WO2018029223A1 (en) * 2016-08-08 2018-02-15 Industriale Chimica S.R.L. PROCESS FOR THE PREPARATION OF 3ß-HYDROXY-17-(1H-BENZIMIDAZOL-1-YL)ANDROSTA-5,16-DIENE
IT201600121375A1 (it) * 2016-11-30 2018-05-30 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
ES3026226T3 (en) * 2018-02-13 2025-06-10 Dana Farber Cancer Inst Inc Cyclin-dependent kinase degraders and methods of use
CA3089588A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase inhibitors and methods of use
US12410194B2 (en) 2019-11-26 2025-09-09 Dana-Farber Cancer Institute, Inc. Potent and selective azaindole inhibitors of CDK8 and CDK19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA27440A (en) 1887-08-16 James T. Walsh Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (enExample) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5994335A (en) 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
PL1660115T3 (pl) 2003-07-29 2011-11-30 Dompe Spa Farmaceutyczna kombinacja G-CSF i PLGF użyteczna wobec komórek macierzystych krwi
EA019560B1 (ru) * 2005-03-02 2014-04-30 Юнивесити Оф Мэриленд, Балтимор Способ лечения простаты (варианты)

Also Published As

Publication number Publication date
CA2599953A1 (en) 2006-09-08
IL185608A0 (en) 2008-01-06
JP2012255026A (ja) 2012-12-27
DE602006017175D1 (de) 2010-11-11
PL1853619T3 (pl) 2011-03-31
WO2006093993A1 (en) 2006-09-08
EP1853619B1 (en) 2010-09-29
IL210480A0 (en) 2011-03-31
JP5130453B2 (ja) 2013-01-30
IL185608A (en) 2016-06-30
EP1853619A1 (en) 2007-11-14
CN103349664A (zh) 2013-10-16
PL2206719T3 (pl) 2015-03-31
HK1115387A1 (en) 2008-11-28
NZ561571A (en) 2009-09-25
BRPI0607523A2 (pt) 2009-09-08
AU2006218711A2 (en) 2006-09-08
JP2008536807A (ja) 2008-09-11
US20080280864A1 (en) 2008-11-13
KR101380959B1 (ko) 2014-04-04
MX2007010593A (es) 2008-02-20
EP1853619A4 (en) 2009-08-26
CN101155823A (zh) 2008-04-02
US7875599B2 (en) 2011-01-25
PT1853619E (pt) 2011-01-03
ES2528055T3 (es) 2015-02-03
AU2006218711A1 (en) 2006-09-08
ATE482969T1 (de) 2010-10-15
AU2006218711B2 (en) 2010-11-11
EP2206719B1 (en) 2014-10-22
IL210480A (en) 2015-06-30
EA200701872A1 (ru) 2008-06-30
IL210478A0 (en) 2011-03-31
EA019560B1 (ru) 2014-04-30
PT2206719E (pt) 2015-02-05
ZA200708106B (en) 2008-12-31
SI1853619T1 (sl) 2011-01-31
JP5613206B2 (ja) 2014-10-22
ES2353413T3 (es) 2011-03-01
EP2206719A3 (en) 2011-01-05
KR20070120119A (ko) 2007-12-21
EP2206719A2 (en) 2010-07-14
DK1853619T3 (da) 2011-01-10
CA2599953C (en) 2013-08-13
SI2206719T1 (sl) 2015-03-31

Similar Documents

Publication Publication Date Title
DK2206719T3 (en) A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN
US10098896B2 (en) C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
Handratta et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model
Bruno et al. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model
Moreira et al. Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors
US6200965B1 (en) 17-Azolyl steroids useful as androgren synthesis inhibitors
ZA200700958B (en) Novel 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17pMiydroxysteroid dehydrogenase type I
Al-Masoudi et al. New biaryl-chalcone derivatives of pregnenolone via Suzuki–Miyaura cross-coupling reaction. Synthesis, CYP17 hydroxylase inhibition activity, QSAR, and molecular docking study
Hou et al. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer
US20080306164A1 (en) New 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17beta-hydroxy steroid dehydrogenase type 1
SK40895A3 (en) 17-beta-substituted 4-azaandrostane derivatives, pharmaceutical compositions containing them and process for preparing same
HK1115387B (en) 3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene for use in the treatment of a prostate disease